Trump Administration Negotiates Affordable Weight-Loss Drug Pricing via TrumpRx
The TRUMP administration is in advanced talks with pharmaceutical giants Eli Lilly and Novo Nordisk to offer weight-loss drugs at reduced prices through TrumpRx, a direct-to-consumer platform slated for launch in early 2026. Key medications like Wegovy and Zepbound could be priced as low as $149 and $249 per month, respectively, under the proposed arrangement.
Medicare and Medicaid coverage expansions for these drugs are also under discussion, signaling a potential shift in accessibility for millions of Americans. President Trump is expected to formally announce the initiative pending final negotiations.
The MOVE comes as demand for GLP-1 receptor agonists surges globally, with Novo Nordisk's Ozempic and Eli Lilly's experimental orforglipron potentially joining the TrumpRx formulary pending regulatory approvals. Both companies confirmed active negotiations to improve affordability of their metabolic health therapeutics.
